Why the study?
Cancer chemotherapy with doxorubicin causes multiorgan toxicities, particularly cardiotoxicity, which represents a major limitation of its clinical use.
Does α-Bisabolol attenuate doxorubicin-induced acute cardiotoxicity in rats?
Population
Rats with DOX-induced acute cardiotoxicity
Comparison
BSB (25 mg/kg orally twice daily) vs DOX alone
Design
Animal experimental study
Follow-up
Five days
Authors
Loading...
α-Bisabolol merits dose-optimization studies in larger models; leaves open clinical translation for doxorubicin cardiotoxicity prevention.
Does α-Bisabolol attenuate doxorubicin-induced acute cardiotoxicity in rats?
α-Bisabolol demonstrates cardioprotective effects against doxorubicin-induced acute cardiotoxicity in rats by modulating multiple oxidative and inflammatory signaling pathways.
Meeran et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: